cas 1715960-61-4|| where to buy methyl 3-methyl-2,3-dihydro-1H-indole-4-carboxylate

Nom du produit:methyl 3-methyl-2,3-dihydro-1H-indole-4-carboxylate

IUPAC Name:methyl 3-methyl-2,3-dihydro-1H-indole-4-carboxylate

Unité d'emballage	Stock disponible	Prix($)	Quantité

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1715960-61-4 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:1715960-61-4; Formule moléculaire:C11H13NO2; Point de fusion:-; Code SMILES:COC(=O)C1=C2C(C)CNC2=CC=C1; Densité:

: Numéro de catalogue:CM1075216; Poids moléculaire:191.23; Point d'ébullition:; N° Mdl:; Stockage:

: Indolines; Indoline is an aromatic heterocyclic organic compound with the chemical formula C8H9N. The compound is based on the indole structure, but the 2-3 bond is saturated. Indoles and their derivatives continue to inspire the development of synthetic organic chemistry even years after their discovery. The specific scaffold is a privileged structure and is ubiquitous in pharmaceuticals and biologically active compounds. Fused indolines as indole derivatives are of particular interest as they are often found in natural products and bioactives such as strychnine and tryptanthrins (alkaloids), mitosanes and mitosenes (antitumor activity) and isatisine (antiviral activity).

: Bexicaserin; Longboard announced positive topline data from the PACIFIC Study evaluating bexicaserin (LP352), a potentially best-in-class and highly selective, oral, novel 5-HT2C receptor superagonist for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs). The analysis showed that bexicaserin achieved a median seizure reduction of 53.3% in countable motor seizures across the DEE study population. Longboard will rapidly advance bexicaserin's global Phase 3 trial.